OClawVPS.com
Myriad Genetics
Edit

Myriad Genetics

http://www.myriad.com/
Last activity: 19.12.2025
Active
Categories: AdTechCareContentDevelopmentDiagnosticsEmployeeHealthTechMedTechPagePersonal
Myriad discovers and commercializes genetic tests that determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower healthcare costs.


As part of our ongoing commitment to you, we will do our best to ensure that the postings on our page are in line with Myriad’s high-quality standards. However, since we unfortunately can’t always monitor every posting or conversation, we expect that our Facebook followers will not post content that falls into the following categories. Myriad reserves the right to remove postings that are:

* abusive, defamatory, threatening or obscene
* fraudulent, deceptive or misleading
* attacking any Myriad Genetics employee by using name or title
* in violation of any intellectual property right of another
* in violation of any law or regulation
* otherwise offensive
* suggestive of new product innovations or advertising ideas
* spam or commercial solicitation

We encourage engaging conversation and appreciate your adherence to our posting guidelines.
Likes
15.84K
Followers
6.73K
Followers
51.78K
Website visits
159.6K /mo.
Mentions
60
Location: United States, Utah, Salt Lake City
Employees: 1001-5000
Phone: +1 800-469-7423
Founded date: 1991

Investors 1

Mentions in press and media 60

DateTitleDescription
19.12.2025Zydus ties up with US-based Myriad Genetics to launch cancer-risk assessment diagnostic tests in India-
12.11.2025Laboratory Economics Issues Research Report on U.S. Anatomic Pathology MarketLaboratory Economics has just published the most comprehensive and detailed market research report available on the U.S. Anatomic Pathology Market. This is an ideal resource for preparing business plans and market strategies. POUGHKEEPSIE, ...
01.11.2025This Week In Techdirt History: October 26th – November 1stFive Years Ago This week in 2020, the RIAA tossed out a bogus DMCA claim to get a YouTube downloading tool pulled from Github, and was still flooding Twitch with takedowns that the company was responding to by freaking out and courting a lo...
23.09.2025Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid BiopsySALT LAKE CITY and BOSTON, Sept. 23, 2025 /PRNewswire/ -- Myriad Genetics (Nasdaq: MYGN), a leader in molecular diagnostic testing and precision medicine, and SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision m...
18.06.2025Why Claims Data Alone Leave Gaps in Understanding the Patient JourneyNoah Nasser, CEO at datma In today’s precision medicine landscape, pharmaceutical companies and access teams face a critical challenge: understanding not just whether therapies work, but how they are accessed, adopted, and experienced by re...
05.02.2025Lumea and Myriad Genetics Collaborate to Enhance Access to Biomarker and Hereditary Cancer Tests in BxLinkLumea and Myriad Genetics have partnered to integrate Myriad’s Prolaris® and MyRisk® molecular diagnostic tests into Lumea’s BxLink™ digital pathology platform. LEHI, UT, UNITED STATES, February 5, 2025 /EINPresswire.com/ -- Lumea Inc., a l...
07.11.2024Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial GuidanceHighlights Third quarter revenue grew 11% year-over-year to $213 million, driven by Pharmacogenomics (34%) and Prenatal (10%) and progress on payor coverage and revenue cycle initiatives. Third quarter GAAP net loss improved to $22.1 millio...
18.09.2024Patents for software and genetic code could be revived by two bills in CongressEnlarge / An image from the U.S. Patent and Trademark Office, where in 1874, the newest thing was not software or genetic compositions, but shutter fastenings from H.L. Norton. Andrew Harrer/Bloomberg via Getty Images reader comments 96 The...
06.08.2024Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%Highlights Second quarter revenue grew 15% year-over-year to $212 million, driven by Prenatal (25%), Pharmacogenomics (22%), and Hereditary Cancer (19%). Second quarter GAAP earnings per share improved to $(0.41) from $(1.42) in the second ...
06.08.2024Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%Highlights Second quarter revenue grew 15% year-over-year to $212 million, driven by Prenatal (25%), Pharmacogenomics (22%), and Hereditary Cancer (19%). Second quarter GAAP earnings per share improved to $(0.41) from $(1.42) in the second ...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In